Browse by Countries

Request/Offer Detail

Title: Anti-TnC-A1 Immunocytokine, scFv (F16)-IL2
TypeName: Business Offer
Request Date:2017/07/31
Country: United States
Summary: This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-TnC-A1 scFv to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the TnC-A1 as well as the biological activity of IL2. This fusion of cytokine to antibody fragment scFv allows for a targeted delivery and improves efficacy and pharmacokinetics. This immunocytokine was designed for treating solid tumors.
Description: This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-TnC-A1 scFv to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the TnC-A1 as well as the biological activity of IL2. This fusion of cytokine to antibody fragment scFv allows for a targeted delivery and improves efficacy and pharmacokinetics. This immunocytokine was designed for treating solid tumors. http://www.creativebiolabs.net/Anti-TnC-A1-Immunocytokine-scFv-F16-IL2-22493.htm
Advantages:
Comments:
RequestId: 381
Name:Creative Biolabs
Telphone:
Email:marketing@creative-biolabs.com

Sponsors

smartportal sponsors